Live Breaking News & Updates on Institute for the future of knowledge

Last month marked a watershed in global efforts to fight the Covid-19 pandemic. US pharmaceutical company Pfizer and its German partner BioNTech announced that they had successfully developed a Covid-19 vaccine that has a 95% efficacy rate (the highest success rate thus far).
The vaccine has passed a late-stage clinical trial and the company has the capacity to produce more than 1 billion doses by 2021. This announcement ignited hope across a world that has been devastated by Covid-19 since it was first discovered in Wuhan, China, in late 2019.
Moderna, another US firm, reported earlier in the same month that its vaccine candidate has a 94% efficacy rate. Russia’s Sputnik V was the first vaccine to show an efficacy rate of more than 90%, having reported a 92% success rate on 11 November for the interim trial results. The UK’s Oxford-AstraZeneca vaccine has an efficacy rate of more than 70%, with capacity to produce around 3 billion doses by 2021. ....

Germany , Moscow , Moskva , Russia , United-states , United-kingdom , Washington , China , Beijing , Johannesburg , Gauteng , South-africa